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The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution Leukemia (2015) 29, 1435-1437; doi:10.1038/leu.2015.7
Multiple myeloma (MM) pathogenesis has been explained for many years by the cancer biology dogma introduced in 1976 by Peter Nowell: 1 first, a single plasma cell would be immortalized by an error in the immunoglobulin genes rearrangement process; then, a progressive stepwise acquisition of somatic cell mutations would induce a sequential selection, leading to domination by the fittest clone. 2 In line with this idea of 'myeloma stability', singlenucleotide polymorphism arrays studies in diagnostic-relapse paired samples have revealed the presence of common clonal characteristics. 3 Biologically, the M-protein remains usually constant across MM evolution, to the point that it is conventionally used to monitor treatment response and disease progress. Further, the variable domain of the rearranged immunoglobulin heavychain genes (or CDR3 region) has been used as a patient-specific myeloma fingerprint in minimal residual disease (MRD) studies. 4 However, massive genome studies with next-generation sequencing have challenged this concept in MM, showing a significant intraclonal heterogeneity at diagnosis with the possible presence of several clonal progenitors or tumor-initiating cells. Therapeutic or ecosystem-dependent selection pressures would drive the alternating dominance of these clones over time. 5 In this study, we have characterized and compared the highly tumor-specific CDR3 region in 52 paired samples from 26 patients with MM obtained at diagnosis and progression or at two different timepoints of progression, aiming (1) to assess monoclonality in MM evolution by means of the analysis of the CDR3 sequence, and (2) to further support ASO RQ-PCR approaches for MRD in MM, based on the constancy and specificity of the CDR3 region.
Genomic DNA from 52 unselected samples of 26 patients diagnosed with MM was isolated using conventional methods. Pairs corresponded to diagnosis/progression samples in 19 cases or to two different time points of progressive disease in seven cases; 50 samples proceeded from bone marrow and 2 from extramedullary tissues (testes and spleen). PCR amplification was performed according to the BIOMED-2 methods. 6 The clonal products were identified by fragment analysis and directly sequenced in an ABI 3130 DNA Sequencer (Applied Biosystems, Foster City, CA, USA). Sequencing was performed using Big-Dye terminators (Applied Biosystems). Germline VH, DH and JH segments from complete rearrangements were identified by comparison with public databases. CDR3 region was identified and highlighted for analysis and comparison between paired samples.
We analyzed 52 samples from 26 patients with MM obtained at diagnosis and progression or at two timepoints of progressive disease. Time between sampling varied from o 1 year to 46 years (median, 2 years). The M-protein subtype remained stable in all cases except in one pair ( Table 1 , case 16), associated with a λ light-chain escape phenomenon. All pairs were obtained from bone marrow except for two ( Table 1 , cases 25 and 26), corresponding to bone marrow and extramedullary disease (spleen and testes). Also, two major cytogenetic changes were identified ( Table 1 ; in case 8, an increased percentage of 13q14 deletion from 7 to 54% was detected and in case 24, of 17p (p53) deletion from 5 to 87%). Treatments administered between sampling are detailed in Table 1 .
VDJH gene sequence analysis has been performed in MM, aiming to determine the B-cell origin of the clonal plasma cell and/or to assess the presence of intraclonal heterogeneity. 7 On the basis of the presence of somatic hypermutations, results consistently confirm the post-germinal origin of the pathological plasma cell, excluding intraclonal variation due to the constancy of the nucleotide sequence. Interestingly however, consecutive samples have been anecdotally analyzed, mainly to assess VDJH patterns of transition from MGUS (monoclonal gammopathy of undetermined significance) to MM. 8, 9 We identified the sequence of the CDR3 region in all samples and then compared the obtained results between the two samples in the 26 pairs. The sequence of nucleotides was constantly identical between all the samples, including cases with significant differences within the pair, such as major cytogenetic changes, light-chain escape, extramedullar vs bone marrow infiltration, and relapsed (and therefore, treatment selected) vs refractory disease (data not shown). Similar results were provided by Ralph et al. 9 in a series of 16 patients using size-based methods and partly confirmed by sequencing. From our study, using PCR amplification and direct Sanger sequencing, we can conclude that the main tumor clone in MM retains a specific signature across disease evolution that allows the identification of samples as evolutionary related.
Next-generation sequencing studies have revealed a highly complex clonal architecture in MM, with a Darwinian-like evolution in a branching manner, leading to substantial clonal diversity and genetic heterogeneity. Although the M-protein subtype remains unchanged in most of the patients with MM, the loss of the immunoglobulin heavy chain (escape phenomenon) has been described. 10 Further, major cytogenetic changes between diagnosis and relapse have been documented, especially in cases of extramedullary disease. Our study shows that the dominant myeloma clone, even in the setting of a clinically and genetically unstable picture, retains a unique and specific IGH rearrangement, unaffected by the selection pressure induced by the treatment/s exposure and constant across disease progress.
These results also provide further support for molecular MRD techniques. The high rate of complete responses (up to 50-60%) currently achieved in MM has prompted the use of new Accepted article preview online 8 January 2015; advance online publication, 27 January 2015 techniques for disease assessment. 11 Today, ASO RQ-PCR, based on the use of specific primers and probes complementary of the VDJH rearrangement, continues to be the most sensitive approach. 4, 12 The main limitation of this approach is a low applicability rate owing to the inability to identify the VDJH rearrangement in many cases. 4 A further pitfall of this technique would be the potential instability of PCR targets over time (owing to genomic changes in the target region), which would induce false-negative results. In B-cell precursor-ALL, where the continuing and secondary rearrangements throughout the disease course is common, 13 this change is estimated to occur in 30-40% of the cases. 13, 14 This problem has not been deeply evaluated in MM. Previous results from our group in 102 patients with MM identified seven intriguing discordances between ASO RQ-PCR and multiparameter flow cytometry (MFC), PCR-/MFC+, which could be explained by changes in the PCR target. With the present study, we can confirm that no changes happen in any part of the VDJH clonal rearrangement in MM evolution. Therefore, the abovementioned discordances cannot be explained by changes in the CDR3 region of the dominant clone, and should be interpreted either as false negatives of the PCR or as false positives of MFC. We can thus conclude that the junction region of the IgH rearrangement in MM is stable and can be used as a target for MRD assessment by ASO RQ-PCR and more, also by deep-sequencing methods, as it constantly identifies the myeloma cells responsible for relapse. 15 In conclusion, our results show that, in the dominant myeloma clone, the CDR3 region of IGH remains constant across all the stages of disease evolution. This major clone signature is not modified by clinical or biological changes in the disease nor under different treatment pressures; accordingly, it would thus be responsible for disease relapses and progression, and could be used as a MRD target. Assuming that the CDR3 region remains stable, the recently raised concept of clonal tiding in MM should not be interpreted as a poly/oligoclonal but subclonal. In summary, in MM tides can be subclonal, but the ocean remains monoclonal.
